Sun Pharmaceutical Industries Ltd. Stock Analysis SUNPHARMA.NS

Sun Pharmaceutical Industries Ltd. engages in manufacturing, developing, and marketing of pharmaceuticals products. The company is headquartered in Mumbai, Maharashtra and currently employs 43,000 full-time employees. The firm's global specialty portfolio spans products in dermatology, ophthalmology, and onco-dermatologym, among others. The firm manufactures and markets a large basket of pharmaceutical formulations across chronic and acute therapies, including generic, branded generics, specialty and complex products, over-the-counter (OTC), antiretrovirals (ARV), Active Pharmaceutical Ingredients (API), and intermediates. Its portfolio spans multiple dosage forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, Bromsite, Xelpros, and others. Its portfolio also includes UNLOXCYTTM, an anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma.